ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $367,201 | -14.3% | 17,620 | -1.5% | 0.03% | -12.9% |
| Q2 2023 | $428,346 | +27.3% | 17,885 | 0.0% | 0.03% | +29.2% |
| Q1 2023 | $336,596 | +18.2% | 17,885 | 0.0% | 0.02% | +9.1% |
| Q4 2022 | $284,729 | -2.8% | 17,885 | 0.0% | 0.02% | -8.3% |
| Q3 2022 | $293,000 | +16.3% | 17,885 | 0.0% | 0.02% | +20.0% |
| Q2 2022 | $252,000 | -41.9% | 17,885 | -0.1% | 0.02% | -31.0% |
| Q1 2022 | $434,000 | +3.8% | 17,910 | 0.0% | 0.03% | +7.4% |
| Q4 2021 | $418,000 | +40.7% | 17,910 | 0.0% | 0.03% | +28.6% |
| Q3 2021 | $297,000 | -32.0% | 17,910 | 0.0% | 0.02% | -38.2% |
| Q2 2021 | $437,000 | -5.2% | 17,910 | +0.1% | 0.03% | -22.7% |
| Q1 2021 | $461,000 | -53.2% | 17,885 | -3.0% | 0.04% | -56.9% |
| Q4 2020 | $985,000 | +24.4% | 18,429 | -4.0% | 0.10% | +67.2% |
| Q3 2020 | $792,000 | -8.9% | 19,204 | +7.2% | 0.06% | -53.4% |
| Q2 2020 | $869,000 | -7.8% | 17,920 | -18.7% | 0.13% | +10.1% |
| Q4 2019 | $943,000 | – | 22,042 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |